MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?

Weight gain is a therapy limiting and very frequent adverse effect of many second-generation antipsychotic (SGA) drugs. The human melanocortin four receptor (MC4R) is a very promising candidate gene possibly influencing SGA-related weight gain. The rs489693 polymorphism near the MC4R gene was associated with SGA-related weight gain in a genome-wide association study. We tried to replicate these results in our independent naturalistic study population. From 341 Caucasian inpatients receiving at least one SGA drug (olanzapine, clozapine, risperidone, paliperidone, quetiapine or amisulpride), carriers homozygous for the rs489693 A-allele (n = 35) showed a 2.2 times higher weight increase (+2.2 kg) than carriers of the CC-genotype (+1 kg) after 4 wk of treatment (analysis of covariance, p = 0.039). We revealed an even stronger effect in a subpopulation without weight gain inducing co-medication (factor 3.1, +2.8 kg, p = 0.044, (n = 16 of 169)) and in first episode patients (factor 2.7, +2.7 kg, p = 0.017, (n = 13 of 86)). Our results confirm the rs489693 A-allele as a possible risk factor for SGA-related weight gain.

[1]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[2]  W. Fleischhacker,et al.  The clinical implications of weight gain in schizophrenia. , 2001, The Journal of clinical psychiatry.

[3]  Annette Lee,et al.  Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. , 2012, Archives of general psychiatry.

[4]  B. Kinon,et al.  Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders , 2005, Journal of clinical psychopharmacology.

[5]  J. M. Langosch,et al.  Gewichtsveränderungen unter Therapie mit Psychopharmaka , 2006 .

[6]  J. J. Stolker,et al.  Reasons for switching between antipsychotics in daily clinical practice. , 2005, Pharmacopsychiatry.

[7]  G. Chandak,et al.  Association between Common Polymorphism near the MC4R Gene and Obesity Risk: A Systematic Review and Meta-Analysis , 2012, PloS one.

[8]  S. Leucht,et al.  Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain , 2013, Journal of clinical psychopharmacology.

[9]  J. Kennedy,et al.  Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications , 2012, Molecular Psychiatry.

[10]  M. Jarvelin,et al.  A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity , 2007, Science.

[11]  Zhen‐Chuan Fan,et al.  Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients , 2009, Journal of cellular and molecular medicine.

[12]  J. Kane,et al.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.

[13]  M. Morrell,et al.  The Expert Consensus Guideline Series Treatment of Epilepsy , 2001, Epilepsy & Behavior.

[14]  G. Currier,et al.  Introduction: Methods, Commentary, and Summary , 2005 .

[15]  S. Stahl.  Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. , 1899, The Journal of clinical psychiatry.

[16]  T. Hardy,et al.  Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder , 2008, BMC psychiatry.

[17]  T. Wilens,et al.  Impact of substance use disorder on ADHD and its treatment. , 2007, The Journal of clinical psychiatry.

[18]  J. Kane,et al.  Optimizing pharmacologic treatment of psychotic disorders , 2003 .

[19]  Subhajyoti De,et al.  Common variants near MC4R are associated with fat mass, weight and risk of obesity , 2008, Nature Genetics.

[20]  J. Newcomer,et al.  Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. , 2007, The Journal of clinical psychiatry.

[21]  L. Schärer,et al.  [Psychotropic drug-induced change of weight: a review]. , 2005, Fortschritte der Neurologie-Psychiatrie.

[22]  W. Steimer,et al.  High-speed genotyping of CYP1A2*1F mutation with fluorescent hybridization probes using the LightCycler. , 2003, Pharmacogenomics.

[23]  Y. Tao.  Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity , 2005, Molecular and Cellular Endocrinology.

[24]  T. Frayling,et al.  Piecing together the FTO jigsaw , 2011, Genome Biology.

[25]  P. Weiden,et al.  Obesity as a risk factor for antipsychotic noncompliance , 2004, Schizophrenia Research.